JP2025508912A - ジフェニルジアゾール誘導体を含む医薬組成物および使用の方法 - Google Patents
ジフェニルジアゾール誘導体を含む医薬組成物および使用の方法 Download PDFInfo
- Publication number
- JP2025508912A JP2025508912A JP2024550866A JP2024550866A JP2025508912A JP 2025508912 A JP2025508912 A JP 2025508912A JP 2024550866 A JP2024550866 A JP 2024550866A JP 2024550866 A JP2024550866 A JP 2024550866A JP 2025508912 A JP2025508912 A JP 2025508912A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- pharmaceutical composition
- anle138b
- fatty acids
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22159408 | 2022-03-01 | ||
| EP22159408.8 | 2022-03-01 | ||
| PCT/EP2023/055160 WO2023166045A1 (en) | 2022-03-01 | 2023-03-01 | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508912A true JP2025508912A (ja) | 2025-04-10 |
| JP2025508912A5 JP2025508912A5 (https=) | 2026-03-10 |
Family
ID=80623476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024550866A Pending JP2025508912A (ja) | 2022-03-01 | 2023-03-01 | ジフェニルジアゾール誘導体を含む医薬組成物および使用の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250161273A1 (https=) |
| EP (1) | EP4486340A1 (https=) |
| JP (1) | JP2025508912A (https=) |
| KR (1) | KR20240155237A (https=) |
| CN (1) | CN118715010A (https=) |
| AU (1) | AU2023227368A1 (https=) |
| CA (1) | CA3246018A1 (https=) |
| CL (1) | CL2024002379A1 (https=) |
| IL (1) | IL314952A (https=) |
| MX (1) | MX2024009773A (https=) |
| PE (1) | PE20250781A1 (https=) |
| WO (1) | WO2023166045A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025068949A1 (en) | 2023-09-26 | 2025-04-03 | Teva Pharmaceutical Industries Ltd. | Emrusolmin for use in treating multiple system atrophy |
| KR20250090047A (ko) * | 2023-12-12 | 2025-06-19 | 가천대학교 산학협력단 | 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2687513B1 (en) * | 2008-06-09 | 2020-12-02 | Ludwig-Maximilians-Universität München | Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases |
| KR102671166B1 (ko) * | 2015-12-14 | 2024-05-31 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 3,5-디페닐-디아졸 화합물의 수용성 유도체 |
-
2023
- 2023-03-01 US US18/840,374 patent/US20250161273A1/en active Pending
- 2023-03-01 PE PE2024001775A patent/PE20250781A1/es unknown
- 2023-03-01 WO PCT/EP2023/055160 patent/WO2023166045A1/en not_active Ceased
- 2023-03-01 KR KR1020247029979A patent/KR20240155237A/ko active Pending
- 2023-03-01 JP JP2024550866A patent/JP2025508912A/ja active Pending
- 2023-03-01 CN CN202380024479.XA patent/CN118715010A/zh active Pending
- 2023-03-01 EP EP23707119.6A patent/EP4486340A1/en active Pending
- 2023-03-01 CA CA3246018A patent/CA3246018A1/en active Pending
- 2023-03-01 MX MX2024009773A patent/MX2024009773A/es unknown
- 2023-03-01 AU AU2023227368A patent/AU2023227368A1/en active Pending
- 2023-03-01 IL IL314952A patent/IL314952A/en unknown
-
2024
- 2024-08-08 CL CL2024002379A patent/CL2024002379A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250161273A1 (en) | 2025-05-22 |
| CL2024002379A1 (es) | 2025-01-24 |
| WO2023166045A1 (en) | 2023-09-07 |
| KR20240155237A (ko) | 2024-10-28 |
| EP4486340A1 (en) | 2025-01-08 |
| MX2024009773A (es) | 2024-08-19 |
| IL314952A (en) | 2024-10-01 |
| CA3246018A1 (en) | 2023-09-07 |
| AU2023227368A1 (en) | 2024-07-18 |
| CN118715010A (zh) | 2024-09-27 |
| PE20250781A1 (es) | 2025-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220152058A1 (en) | Methods and compositions for treating various disorders | |
| JP7761372B2 (ja) | 対象におけるマイトファジーを改善するための方法 | |
| JP2017081930A (ja) | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 | |
| BR112012022336A2 (pt) | composições e seus usos para tratar e/ou prevenir doença cardiovascular | |
| KR20140101333A (ko) | 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료 | |
| JP2018538273A (ja) | 虚血性脳卒中を処置するための組成物および方法 | |
| JP2025508912A (ja) | ジフェニルジアゾール誘導体を含む医薬組成物および使用の方法 | |
| MX2015001889A (es) | Laquinimod para tratamiento de trastornos mediados por receptor de canabinoide tipo 1 (cb1). | |
| WO2011071805A1 (en) | 4-methylpyrazole formulations | |
| US20150174118A1 (en) | Use of laquinimod to delay huntington's disease progression | |
| EA052714B1 (ru) | Фармацевтическая композиция, содержащая производные дифенилдиазола, и способ применения | |
| HK40115748A (zh) | 包含二苯基二唑衍生物的药物组合物及其使用方法 | |
| US20240165093A1 (en) | Methods for treating familial chylomicronemia syndrome | |
| KR20240036651A (ko) | 산화성 망막 질환의 진행을 억제하는 방법 | |
| KR20240004706A (ko) | 신경내분비 종양을 치료하기 위한 조성물 및 방법 | |
| CN116323604A (zh) | 5-甲基-1,2,4-噁二唑-3-基化合物的低剂量方案和制剂 | |
| WO2024210195A1 (ja) | 炎症性腸疾患の治療用医薬組成物 | |
| CN110996937A (zh) | 包含dgla的药物组合物及其用途 | |
| KR20260021653A (ko) | IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄 | |
| WO2025068949A1 (en) | Emrusolmin for use in treating multiple system atrophy | |
| CN118742299A (zh) | 监测患者对视网膜氧化性疾病治疗反应的方法 | |
| CA3288236A1 (en) | Pharmaceutical composition for treatment of inflammatory bowel disease | |
| WO2024050562A2 (en) | Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof | |
| TW201404395A (zh) | 以拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）及醋酸格拉替雷（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之組合治療多發性硬化症 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260227 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260227 |